Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and ADC for Patients with Previously Treated HER2+ ...

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic ...

The FDA has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), endocrine therapy, and optionally ...

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Commission (EC) has approved their ...

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial ...

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...

Brain metastases are a major challenge in HER2-positive metastatic breast cancer; epidemiologic series suggest that roughly 30%–50% of patients eventually develop brain involvement, which is ...

FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...

For about 60 percent of patients previously diagnosed with HER2-negative metastatic breast cancer, there may be a treatment available. In the world of breast cancer, a thorough account of many details ...

Researchers at the University of California, Los Angeles have developed a compact, cost-effective diagnostic platform ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...